Full text

Turn on search term navigation

© The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

This Summary of Research summarises results from the BE OPTIMAL (NCT03895203) and BE COMPLETE (NCT03896581) studies and their open-label extension, BE VITAL (NCT04009499). These phase 3 studies looked at how well bimekizumab treatment worked in patients with psoriatic arthritis, and the safety of bimekizumab treatment, over the long term. Two patient groups were included in these studies: patients who had not previously been treated with biologic disease-modifying antirheumatic drugs (bDMARD-naïve; BE OPTIMAL) and patients who had a poor response or were intolerant to tumour necrosis factor (TNF) inhibitors (BE COMPLETE). These studies showed that the beneficial effects of bimekizumab treatment on patients’ symptoms reported at year 1 of treatment were sustained up to 2 years, regardless of whether patients were bDMARD-naïve or had previously had a poor response or intolerance to TNF inhibitors. Bimekizumab was well tolerated up to 2 years. The data from this study may help clinicians and patients when they are making shared decisions on treatment options for psoriatic arthritis.

Details

Title
Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
Author
Mease, Philip J. 1   VIAFID ORCID Logo  ; Merola, Joseph F. 2 ; Tanaka, Yoshiya 3 ; Gossec, Laure 4 ; McInnes, Iain B. 5 ; Ritchlin, Christopher T. 6 ; Landewé, Robert B. M. 7 ; Asahina, Akihiko 8 ; Ink, Barbara 9 ; Heinrichs, Andrea 10 ; Bajracharya, Rajan 9 ; Shende, Vishvesh 9 ; Coarse, Jason 11 ; Coates, Laura C. 12 

 Providence-Swedish Medical Center and University of Washington, Department of Rheumatology, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657) 
 UT Southwestern Medical Center, Department of Dermatology and Department of Medicine, Division of Rheumatology, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121) 
 University of Occupational and Environmental Health, Japan, The First Department of Internal Medicine, Kitakyushu, Japan (GRID:grid.271052.3) (ISNI:0000 0004 0374 5913) 
 Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France (GRID:grid.7429.8) (ISNI:0000000121866389); AP-HP, Pitié-Salpêtrière Hospital, Rheumatology Department, Paris, France (GRID:grid.411439.a) (ISNI:0000 0001 2150 9058) 
 University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X) 
 University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Rochester, USA (GRID:grid.16416.34) (ISNI:0000 0004 1936 9174) 
 Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, The Netherlands (GRID:grid.16416.34); Zuyderland MC, Heerlen, The Netherlands (GRID:grid.16416.34) 
 The Jikei University School of Medicine, Department of Dermatology, Tokyo, Japan (GRID:grid.411898.d) (ISNI:0000 0001 0661 2073) 
 UCB, Slough, UK (GRID:grid.418727.f) (ISNI:0000 0004 5903 3819) 
10  UCB Biosciences GmbH, Monheim am Rhein, Germany (GRID:grid.420204.0) (ISNI:0000 0004 0455 9792) 
11  UCB, Morrisville, USA (GRID:grid.469275.b) (ISNI:0000 0004 0535 721X) 
12  Oxford University Hospitals NHS Trust, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford, UK (GRID:grid.410556.3) (ISNI:0000 0001 0440 1440) 
Pages
609-612
Publication year
2025
Publication date
Aug 2025
Publisher
Springer Nature B.V.
ISSN
21986576
e-ISSN
21986584
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3228984673
Copyright
© The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.